News
Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing startup for about $1.3 billion.
Summary. Eli Lilly's $1.3B offer for Verve Therapeutics is a lifeline, providing a 70%+ premium and a solid exit for Verve investors. VERV struggled as a standalone due to tough gene therapy ...
Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.
Eli Lilly and Company announced that it has acquired Verve Therapeutics, a clinical-stage biotech company developing in vivo gene editing medicines for atherosclerotic cardiovascular disease (ASCVD).
Eli Lilly (NYSE:LLY) has agreed to acquire Boston-based gene editing startup Verve Therapeutics (NASDAQ:VERV) for up to $1.3B. Pursuant to the agreement, Lilly will commence a tender offer to ...
INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for ...
Summary. Eli Lilly is acquiring Verve Therapeutics for $10.5/share plus a potential $3/share CVR, totaling up to $13.5/share. The deal values Verve at up to $1.3 billion, reflecting a 113% premium ...
Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising to $1.3bn, with market analysis describing the deal as a “bargain”.
Eli Lilly LLY 0.62 % increase; green up pointing triangle agreed to acquire Verve Therapeutics VERV-0.27 % decrease; red down pointing triangle for about $1 billion upfront, adding a potential ...
Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement, the ...
Eli Lilly is taking a big swing into gene editing with a deal to buy Verve (NASDAQ:VERV) Therapeutics for up to $1.3 billion, paying $10.50 per share in cash plus a contingent right worth up to $3 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results